[Laboratory and clinical studies of T-1982 (cefbuperazone) in pediatric infectious diseases].
Laboratory and clinical studies were carried out with T-1982 (cefbuperazone) in pediatric infectious diseases. Results were as follows. 1. The average serum concentrations of T-1982 following intravenous injection of 10 mg/kg and 20 mg/kg were 35.3, 64.7 micrograms/ml at 30 minutes, 25.5, 41.5 micrograms/ml at 1 hour, 12.4, 21.8 micrograms/ml at 2 hours, respectively. Dose-response was observed. Urinary recovery rates of T-1982 during 6 hours after injection of 10 mg/kg and 20 mg/kg were 57.3% and 73.6%, respectively. 2. The antibacterial activity of T-1982 against clinically isolated organisms was determined. T-1982 was more active than cefazolin and cefmetazole against K. pneumoniae, H. influenzae and E. coli. It was also effective against ampicillin-resistant E. coli. 3. Thirty-seven patients received daily 30-69 mg/kg of T-1982 t.i.d. for 5-9 days. The rate of satisfactory clinical response was 91.9%. 4. Side effects were diarrhea in 4 cases, diarrhea and rash in 1 case and slight elevation of GOT and GPT in 1 case. But these were transient and mild.
D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D002513:Cephamycins / Q000378:metabolism / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004352:Drug Resistance, Microbial; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D007711:Klebsiella pneumoniae / Q000187:drug effects; D008297:Male; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000378:metabolism
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D002513:Cephamycins; C035978:cefbuperazone